Treatment of chronic viral hepatitis;Biologisk behandling af virus- Hepatitis

Ugeskrift for Laeger

Volumn 170, Issue 24, 2008, Pages 2137-2140

  Pedersen, Court ^a   Pedersen, Christian Ross ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RIBAVIRIN;

ARTICLE; DRUG COMBINATION; HEPATITIS B; HEPATITIS C; HUMAN; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; RIBAVIRIN; TREATMENT OUTCOME;

EID: 45749111468     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Thomas HC. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol 2007;47:588-97.
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51.
3. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
6. Silva M, Poo J, Wagner F et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006;45:204-13.
7. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-81.
8. Liaw YF, Tai DI, Chu CM et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
9. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
10. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.